Maravai LifeSciences Q4 revenue drops less than expected

Maravai Lifesciences Holdings

25/02/2026 21:17

Overview

Life science reagents provider reported smaller-than-expected drop in Q4 revenue

Adjusted EBITDA for Q4 beat analyst expectations

Revenue decline due to reduced CleanCap orders for vaccine programs

Outlook

Maravai expects full-year 2026 revenue between $200 mln and $210 mln

Company projects full-year 2026 Adjusted EBITDA between $18 mln and $20 mln

Result Drivers

CLEANCAP ORDERS - TriLink segment revenue fell 17.4% in Q4 due to reduced CleanCap orders for vaccine programs

HCP KITS DEMAND - Cygnus segment revenue increased 4.1% in Q4 driven by strong demand for HCP kits

COST REDUCTION - Positive Adjusted EBITDA in Q4 attributed to organizational restructuring and cost reduction

Company press release: ID:nBwpLk9Ca

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$49.90 mln
$49.05 mln (11 Analysts)
Q4 Net Income
-$63 mln
Q4 Adjusted EBITDA
Beat
$500,000
-$4.02 mln (10 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Maravai LifeSciences Holdings Inc is $4.50, about 44.2% above its February 24 closing price of $3.12

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)